NASDAQ:VNDAVanda Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.49 +0.03 (+0.26 %) (As of 06/4/2020 01:39 PM ET) Add Compare Share Today's Range$11.29Now: $11.49▼$11.5450-Day Range$10.42MA: $11.43▼$12.0252-Week Range$7.12Now: $11.49▼$17.85Volume13,444 shsAverage Volume699,821 shsMarket Capitalization$626.78 millionP/E Ratio5.37Dividend YieldN/ABeta0.48 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingVanda Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Vanda Pharmaceuticals has a potential upside of 39.3% from its current price of $11.49.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesVanda Pharmaceuticals has received 497 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVanda Pharmaceuticals has received 427 “underperform” votes. (Add your “underperform” vote.)Community SentimentVanda Pharmaceuticals has received 53.79% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote “Outperform” if you believe VNDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $111,824.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions98.62% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow by 87.50% in the coming year, from $0.24 to $0.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is 5.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.28.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is 5.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.63.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.1 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.99 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VNDA Previous Symbol CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone202-734-3400Debt Debt-to-Equity RatioN/A Current Ratio6.09 Quick Ratio6.07Price-To-Earnings Trailing P/E Ratio5.37 Forward P/E Ratio47.88 P/E GrowthN/A Sales & Book Value Annual Sales$227.19 million Price / Sales2.76 Cash Flow$2.18 per share Price / Cash Flow5.27 Book Value$7.70 per share Price / Book1.49Profitability EPS (Most Recent Fiscal Year)$2.11 Net Income$115.55 million Net Margins49.12% Return on Equity30.60% Return on Assets25.65%Miscellaneous Employees270 Outstanding Shares54,550,000Market Cap$626.78 million Next Earnings Date7/29/2020 (Estimated) OptionableOptionable NASDAQ:VNDA Rates by TradingView Receive VNDA News and Ratings via Email Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions How has Vanda Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Vanda Pharmaceuticals' stock was trading at $10.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VNDA shares have increased by 8.4% and is now trading at $11.49. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Vanda Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Vanda Pharmaceuticals. When is Vanda Pharmaceuticals' next earnings date? Vanda Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Vanda Pharmaceuticals. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $0.01. The biopharmaceutical company earned $58 million during the quarter, compared to the consensus estimate of $57.53 million. Vanda Pharmaceuticals had a net margin of 49.12% and a return on equity of 30.60%. View Vanda Pharmaceuticals' earnings history. What guidance has Vanda Pharmaceuticals issued on next quarter's earnings? Vanda Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, May, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $247.77 million. What price target have analysts set for VNDA? 4 analysts have issued 12 month price targets for Vanda Pharmaceuticals' shares. Their forecasts range from $12.00 to $25.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price. View analysts' price targets for Vanda Pharmaceuticals. Has Vanda Pharmaceuticals been receiving favorable news coverage? Media headlines about VNDA stock have been trending somewhat negative on Thursday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutVanda Pharmaceuticals. Are investors shorting Vanda Pharmaceuticals? Vanda Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 4,320,000 shares, a decrease of 6.3% from the April 30th total of 4,610,000 shares. Based on an average trading volume of 791,600 shares, the short-interest ratio is currently 5.5 days. Currently, 8.3% of the company's shares are sold short. View Vanda Pharmaceuticals' Current Options Chain. Who are some of Vanda Pharmaceuticals' key competitors? Some companies that are related to Vanda Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Zogenix (ZGNX), NVIDIA (NVDA), Array Biopharma (ARRY), Micron Technology (MU), Exelixis (EXEL) and ImmunoGen (IMGN). Who are Vanda Pharmaceuticals' key executives? Vanda Pharmaceuticals' management team includes the following people: Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec. What is Vanda Pharmaceuticals' stock symbol? Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA." Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.69%), State Street Corp (5.20%), Acadian Asset Management LLC (2.14%), Nuveen Asset Management LLC (1.47%), Geode Capital Management LLC (1.40%) and Bank of New York Mellon Corp (1.11%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View institutional ownership trends for Vanda Pharmaceuticals. Which major investors are selling Vanda Pharmaceuticals stock? VNDA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Two Sigma Investments LP, Nuveen Asset Management LLC, Wells Fargo & Company MN, Parametric Portfolio Associates LLC, UBS Group AG, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan, and Timothy Williams. View insider buying and selling activity for Vanda Pharmaceuticals. Which major investors are buying Vanda Pharmaceuticals stock? VNDA stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, State Street Corp, Tang Capital Management LLC, Acadian Asset Management LLC, Skandinaviska Enskilda Banken AB publ , Federated Hermes Inc., Pictet Asset Management Ltd., and Profit Investment Management LLC. View insider buying and selling activity for Vanda Pharmaceuticals. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vanda Pharmaceuticals' stock price today? One share of VNDA stock can currently be purchased for approximately $11.49. How big of a company is Vanda Pharmaceuticals? Vanda Pharmaceuticals has a market capitalization of $626.78 million and generates $227.19 million in revenue each year. The biopharmaceutical company earns $115.55 million in net income (profit) each year or $2.11 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe. What is Vanda Pharmaceuticals' official website? The official website for Vanda Pharmaceuticals is www.vandapharma.com. How can I contact Vanda Pharmaceuticals? Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
